Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Nephrology

Understanding Complement Factor H (CFH) Deficiency

At a Glance

Complement factor H deficiency is a rare immune-system disorder in which a missing or faulty protein removes a natural brake on inflammation. The resulting overactivity can harm small blood vessels, kidneys, blood cells, or the retina, but the effects vary widely between people.

Learning that you have a Complement Factor H (CFH) deficiency can feel like being handed a map to a place you never wanted to visit. This condition is exceptionally rare, and because it can affect the kidneys, the blood, and the eyes in different ways, the path forward isn’t always a straight line [1].

At its core, CFH deficiency is a problem with your immune system’s volume control. To understand what is happening in your body, it helps to look at how your immune system is supposed to protect you and what happens when one specific “brake” goes missing.

The Missing Brakes

Your body has a part of the immune system called the complement system. Think of it as a security team that is always “on,” patrolling your bloodstream for bacteria and damaged cells. This system has a specific pathway, called the alternative pathway, that is designed to stay active at a low level so it can respond instantly to threats [2].

Because this system is so powerful, it needs “brakes” to keep it from attacking your own healthy tissues. Factor H (FH) is one of the most important brakes in this system [3]. Its job is to:

  • Identify your own healthy cells so the immune system ignores them [4].
  • Shut down the immune response once a threat is gone [5].
  • Keep the overall level of “immune noise” low enough that it doesn’t cause damage [6].

In CFH deficiency, your body either doesn’t make enough of this protein or makes a version that doesn’t work correctly. Without these brakes, the complement system can stay “stuck” in the on position, eventually causing inflammation and damage to your own organs [7][8].

How CFH Deficiency Shows Up

Because Factor H is supposed to protect the whole body, a deficiency can lead to several different conditions. Most people do not develop all of these; instead, your specific genetic makeup and environmental triggers (like a routine infection) usually push the disease toward one of three main areas, though these can overlap [9][10].

1. Atypical Hemolytic Uremic Syndrome (aHUS)

In aHUS, the overactive complement system causes complement-mediated endothelial injury in the lining of your small blood vessels. This creates tiny blood clots throughout the body, particularly in the kidneys [9]. This process can lead to:

  • Thrombocytopenia: A drop in your platelet count as they are used up in clots (though this may be modest or absent in some patients) [11].
  • Hemolysis: The destruction of red blood cells as they try to squeeze through clogged vessels [9].
  • Acute Kidney Injury: Rapidly declining kidney function because the filtering units are damaged [12].

2. C3 Glomerulopathy (C3G)

C3G is a condition focused primarily on the kidneys. Instead of sudden blood clots, the overactive complement system causes a protein called C3 to deposit directly into the kidney’s filters [13]. Over time, these deposits cause inflammation and scarring, which can lead to protein in the urine (proteinuria) and a decline in kidney function [1]. Note that C3G can present acutely or gradually, and is not caused by Factor H deficiency in every single case.

3. Retinal Disease and Vision Changes

Factor H also plays a critical role in protecting the back of your eye, the retina. When the “brakes” are missing, metabolic waste can build up under the retina in the form of yellow deposits called drusen [14]. While many people develop small drusen as they age (Age-Related Macular Degeneration or AMD), people with CFH deficiency may develop them much earlier or more severely [15][16]. In some cases, this can lead to blurred vision, difficulty seeing at night, or changes in how you perceive colors, though retinal deposits are a rare association and not an inevitable feature for everyone [14][17].

Validating the Complexity

If you feel overwhelmed, it is because this condition truly is complex. You may find that even experienced doctors have to consult specialists in nephrology (kidneys), hematology (blood), and immunology (the immune system) to coordinate your care [18][1].

One of the most difficult parts of a CFH diagnosis is incomplete penetrance. This is a medical term meaning that even if two people have the exact same mutation, one might get very sick while the other has no symptoms at all [19]. This happens because the mutation is often a “predisposition”—it creates the environment for the disease, but it often takes a second trigger, such as an infection, a pregnancy, or another genetic factor, to actually start the immune attack [9][20].

Moving Toward Management

While there is no way to “fix” the missing gene yet, modern medicine has developed ways to manage the downstream damage.

  • Specialized Testing: Doctors can now measure specific markers in your blood to see exactly how active your complement pathways are [21].
  • Targeted Therapies: There are medications (complement inhibitors) designed to block the immune pathway further downstream to prevent complement-mediated endothelial injury [18].
  • Monitoring: Regular blood work and eye exams can help catch changes early, before they cause permanent damage [14][11].

Living with a rare disease requires a different kind of strength. You are managing a condition that most people have never heard of, which can feel isolating. Connecting with patient communities for C3G or aHUS can provide a space where your experience is understood without explanation [1]. Progress in understanding the complement system is moving rapidly, providing more clarity and better management options than were available even a few years ago [22].

Common questions in this guide

What health problems can complement factor H deficiency cause?
CFH deficiency can be associated with atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), and retinal changes. These problems may overlap, and most people do not develop every possible complication.
What kidney problems can CFH deficiency cause?
Overactive complement can injure small blood vessels in the kidneys or cause C3 deposits in the kidney filters. Possible findings include protein in the urine, reduced kidney function, or acute kidney injury; some people may also notice changes in urine amount or color.
Can CFH deficiency affect vision?
CFH deficiency may be associated with drusen, or yellow deposits under the retina, appearing earlier or more extensively than expected. Some people develop blurred vision, difficulty seeing at night, or changes in color perception, but retinal involvement is not inevitable.
How is complement factor H deficiency tested?
Evaluation may include genetic testing for a CFH variant, blood tests that measure complement levels or activity such as C3 and AH50, and testing for an antibody against Factor H. Doctors may also monitor blood counts, kidney function, urine, and eye findings.
Does having a CFH mutation mean I will definitely develop disease?
No. CFH-related disease has incomplete penetrance, meaning some people with the same mutation remain well while others become ill. Infections, pregnancy, or other genetic factors may help trigger disease in someone who is predisposed.
How is CFH deficiency managed?
There is not yet a routine way to correct the underlying CFH gene problem. Complement inhibitors may block the pathway farther downstream, while regular blood work, kidney monitoring, and eye exams can help identify changes early.
Should family members or children be tested for a CFH abnormality?
Because some CFH abnormalities can run in families, ask the clinician managing your condition whether relatives or children should have genetic evaluation. The decision depends on the exact abnormality, family history, and clinical findings.

Get notified when new evidence is published on complement factor H deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    A Narrative Review of C3 Glomerulopathy: From Pathogenesis to Targeted Therapy.

    Jauhal A, Barr B, Girard L, et al.

    Canadian journal of kidney health and disease 2026; (13()):20543581261442656 doi:10.1177/20543581261442656.

    PMID: 42131278
  2. 2

    C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice.

    Zhang Y, Keenan A, Dai DF, et al.

    JCI insight 2020; (5(9)).

    PMID: 32376801
  3. 3

    An Evaluation of the Complement-Regulating Activities of Human Complement Factor H (FH) Variants Associated With Age-Related Macular Degeneration.

    Biggs RM, Makou E, Lauder S, et al.

    Investigative ophthalmology & visual science 2022; (63(12)):30 doi:10.1167/iovs.63.12.30.

    PMID: 36445700
  4. 4

    A Dimerization Site at SCR-17/18 in Factor H Clarifies a New Mechanism for Complement Regulatory Control.

    Dunne OM, Gao X, Nan R, et al.

    Frontiers in immunology 2020; (11()):601895 doi:10.3389/fimmu.2020.601895.

    PMID: 33552059
  5. 5

    Podocytes Produce and Secrete Functional Complement C3 and Complement Factor H.

    Mühlig AK, Keir LS, Abt JC, et al.

    Frontiers in immunology 2020; (11()):1833 doi:10.3389/fimmu.2020.01833.

    PMID: 32922395
  6. 6

    Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.

    Laskowski J, Renner B, Le Quintrec M, et al.

    Kidney international 2016; (90(1)):109-22.

    PMID: 27165610
  7. 7

    Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD.

    Wong EKS, Hallam TM, Brocklebank V, et al.

    Frontiers in immunology 2020; (11()):602284 doi:10.3389/fimmu.2020.602284.

    PMID: 33519811
  8. 8

    Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation.

    Kerr H, Wong E, Makou E, et al.

    The Journal of biological chemistry 2017; (292(32)):13345-13360 doi:10.1074/jbc.M117.795088.

    PMID: 28637873
  9. 9

    Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome.

    Schönauer R, Seidel A, Grohmann M, et al.

    Frontiers in genetics 2019; (10()):465 doi:10.3389/fgene.2019.00465.

    PMID: 31156713
  10. 10

    Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration.

    Lorés-Motta L, van Beek AE, Willems E, et al.

    American journal of human genetics 2021; (108(8)):1367-1384 doi:10.1016/j.ajhg.2021.06.002.

    PMID: 34260947
  11. 11

    A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.

    Yoshida Y, Miyata T, Matsumoto M, et al.

    PloS one 2015; (10(5)):e0124655 doi:10.1371/journal.pone.0124655.

    PMID: 25951460
  12. 12

    Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis.

    Doshi K, Yusuf A, Licht C, et al.

    Pediatric research 2025; (98(2)):491-497 doi:10.1038/s41390-024-03771-7.

    PMID: 39676096
  13. 13

    [Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy].

    Yurova VA, Kozlovskaya NL, Bobrova LA, et al.

    Terapevticheskii arkhiv 2023; (95(6)):475-480 doi:10.26442/00403660.2023.06.202269.

    PMID: 38158966
  14. 14

    Retinal disease in the C3 glomerulopathies and the risk of impaired vision.

    Savige J, Amos L, Ierino F, et al.

    Ophthalmic genetics 2016; (37(4)):369-376 doi:10.3109/13816810.2015.1101777.

    PMID: 26915021
  15. 15

    Complement factor H in AMD: Bridging genetic associations and pathobiology.

    Toomey CB, Johnson LV, Bowes Rickman C

    Progress in retinal and eye research 2018; (62()):38-57 doi:10.1016/j.preteyeres.2017.09.001.

    PMID: 28928087
  16. 16

    Geographic Atrophy in Patients with Age-Related Macular Degeneration Is Associated with Rare Variants in Complement Factor H and Complement Factor I.

    de Breuk A, de Jong S, Bakker B, et al.

    Ophthalmology science 2026; (6(6)):101171 doi:10.1016/j.xops.2026.101171.

    PMID: 42222588
  17. 17

    Evidence for the Pathogenicity of a CFH Variant in a Multigenerational Family with Cuticular Drusen.

    Preiksaitiene E, Gurskytė V, Mikštienė V, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(9)) doi:10.3390/medicina61091649.

    PMID: 41011040
  18. 18

    Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in Taiwan.

    Tseng MH, Lin SH, Tsai JD, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2023; (122(5)):366-375 doi:10.1016/j.jfma.2022.10.006.

    PMID: 36323601
  19. 19

    Long-term data on two sisters with C3GN due to an identical, homozygous CFH mutation and autoantibodies.

    Hackl A, Erger F, Skerka C, et al.

    Clinical nephrology 2020; (94(4)):197-206 doi:10.5414/CN110135.

    PMID: 32870147
  20. 20

    Successful term pregnancy after renal transplant in end-stage renal disease with complement factor H-related mutation: A case report.

    Balwani MR, Pasari A, Kashiv P, et al.

    World journal of transplantation 2026; (16(1)):113117 doi:10.5500/wjt.v16.i1.113117.

    PMID: 41607808
  21. 21

    Systematic review of atypical hemolytic uremic syndrome biomarkers.

    Raina R, Sethi SK, Dragon-Durey MA, et al.

    Pediatric nephrology (Berlin, Germany) 2022; (37(7)):1479-1493 doi:10.1007/s00467-022-05451-2.

    PMID: 35118546
  22. 22

    Complement-Mediated Kidney Disease and Living Donor Transplantation: Tailoring Approaches to Improve Outcomes.

    Memon AA, Lentine KL, Caliskan Y

    Current transplantation reports 2025; (12(1)) doi:10.1007/s40472-025-00466-8.

    PMID: 40385465

This page is for informational purposes only and does not constitute medical advice. A nephrologist, hematologist, immunologist, or eye specialist can interpret your CFH results and recommend care for your situation.